Every material Form 8-K FILANA THERAPEUTICS, INC. has filed with the SEC since September 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Filana Therapeutics reported third-quarter 2026 results with a net loss of $10.7 million, or $0.22 per share, nearly unchanged from $10.8 million a year earlier. The company said the FDA lifted the clinical hold on its simufilam study in September 2026 and expects patient screening to begin by the first quarter of 2027, with year-end 2026 cash guided to $38 million to $42 million.
Q3 2026 net loss was $10.7 million, or $0.22 per share, versus $10.8 million, or $0.22 per share, in Q3 2025.
Cash and cash equivalents were $47.0 million at September 30, 2026, and the company has no debt.
A $31.25 million litigation settlement escrow payment was made on July 23, 2026, recorded as restricted cash.
Net cash used in operations for second-half 2026 is expected to be $11 million to $15 million.
The Fifth Circuit Court of Appeals vacated the Texas District Court's order granting class certification in the securities class action against Filana Therapeutics and certain officers and employees. The case returns to the Texas District Court for further class certification proceedings, and the appeals court made no finding on whether the company's securities traded in an efficient market.
On October 16, 2026, the Fifth Circuit vacated the class certification order.
The class covered purchasers or acquirers of the company's securities between September 14, 2020 and October 12, 2023.
The Fifth Circuit found the district court misapplied the legal standard and did not properly evaluate evidence of market inefficiency.
Further class certification proceedings will take place on remand in the Western District of Texas.
The FDA has lifted the full clinical hold on Filana Therapeutics' IND for a planned Phase 2a study of simufilam in TSC-related epilepsy. Patient screening is expected to begin by the first quarter of 2027, so the hold removal is a development milestone rather than a change in financial results.
FDA lifted the full clinical hold on the simufilam IND, announced September 22, 2026
Planned Phase 2a study: 16-week randomized, double-blind trial at 13 U.S. sites, targeting 40 subjects aged 12 to 55
Patient screening expected to begin by the first quarter of 2027
Company completed trial-readiness work during the hold, including engaging a clinical research organization and identifying sites
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every FILANA THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →